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Abstract
Background:  Substances of abuse, such as opiates, have a variety of immunomodulatory
properties that may influence both neuroinflammatory and neurodegenerative disease processes.
The chemokine CCL2, which plays a pivotal role in the recruitment of inflammatory cells in the
nervous system, is one of only a few chemokines produced by neurons. We hypothesized that
morphine may alter expression of CCL2 by human neurons.
Methods: Primary neuronal cell cultures and highly purified astrocyte and microglial cell cultures
were prepared from human fetal brain tissue. Cell cultures were treated with morphine, and cells
were examined by RNase protection assay for mRNA. Culture supernatants were assayed by
ELISA for CCL2 protein. β-funaltrexamine (β-FNA) was used to block μ-opioid receptor (MOR)s.
Results: Morphine upregulated CCL2 mRNA and protein in neuronal cultures in a concentration-
and time-dependent fashion, but had no effect on CCL2 production in astrocyte or microglial cell
cultures. Immunocytochemical analysis also demonstrated CCL2 production in morphine-
stimulated neuronal cultures. The stimulatory effect of morphine was abrogated by β-FNA,
indicating an MOR-mediated mechanism.
Conclusion:  Morphine stimulates CCL2 production by human neurons via a MOR-related
mechanism. This finding suggests another mechanism whereby opiates could affect
neuroinflammatory responses.
Background
Substances of abuse have been shown to have a number
of immunomodulatory activities [1,2], and drugs such as
opiates have been implicated as a cofactor in the patho-
genesis of neuroinflammatory conditions such as HIV-1
encephalitis [3]. Three classes of opioid receptors (μ, κ,
and δ) have been identified in neurons, and these same
receptors are found in macrophages and lymphocytes,
which suggest opioids serve as communication signals
between neurons and cells of the immune system. There
is substantial evidence that this cross-talk between the
nervous and the immune systems also involves chemok-
ines, which along with neuropeptides and neurotransmit-
ters, appear to function as a third major system of
communication within the brain [4]. Examples of connec-
tions between the opioid and chemokine signalling sys-
tems include the demonstration that a μ-opioid receptor
(MOR) selective agonist increases the expression of CCL2,
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CCL5 and CXCL10 mRNA and protein in human periph-
eral blood mononuclear cells [5] and that morphine mod-
ulates chemokine gene regulation in human astrocytes
[6].
The chemokine CCL2 is an inflammatory mediator which
recruits monocyte/macrophage-derived cells into areas of
damage within the central nervous system (CNS). CCL2 is
produced by a variety of cell types including macrophages
and endothelial cells, but in the CNS, release of CCL2 has
been classically attributed to astrocytes and microglia [7].
The chemotactic properties of CCL2 extend to T-lym-
phocytes, natural killer cells, basophils, mast cells, and
dendritic cells [8]. Recent studies have also shown that
neurons themselves constitutively produce CCL2. Expres-
sion of CCL2 by developing human neurons was demon-
strated by immunocytochemical and western blotting
methods [9]. Both CCL2 mRNA and soluble CCL2 were
identified in the NT2 neuronal cell line [10]. CCL2 was
also shown to be released from remote neurons in a rat
nerve injury model [11], from murine neurons in a com-
pression model [12], and from murine neurons in an
ischemia model [13]. Studies of CCL2 in rat neurons have
revealed that constitutive neuronal expression of CCL2 is
highly regionalized and in the rat model, is found in both
cholinergic and dopaminergic neurons [14]. Although the
cellular source has not been definitively established,
CCL2 is upregulated in such neuroinflammatory proc-
esses as HIV dementia (HAD) [8,15], experimental aller-
gic encephalomyelitis [16], and multiple sclerosis [17]
and may integral to recruitment of neural progenitors to
sites of neuroinflammation [18].
Based upon the established importance of CCL2 in HAD
[15,19-21] and mounting evidence that opiates foster the
neuropathogenesis of HIV-1 [22], the purpose of the
present study was to test the hypothesis that the opioid
agonist morphine can alter CCL2 expression in human
neurons. We have found that morphine robustly
enhanced CCL2 expression, that this effect is unique to
neurons, and that it appears to involve MORs.
Methods
Reagents
The following reagents were purchased from the indicated
sources: fetal bovine serum (FBS) (Hyclone, Logan, UT);
morphine sulfate, Dulbecco's modified Eagle medium
(DMEM), penicillin, streptomycin, Hanks' balanced salt
solution (HBSS), trypsin, bovine serum albumin, polyox-
yethylenesorbitan monolaurate (Tween 20), PBS, and
paraformaldehyde, (Sigma, St. Louis, MO); neural basal
medium and B-27 serum-free supplement (Invitrogen,
Carlsbad, CA); anti-neuron nuclei (NeuN; a neuronal
marker) and anti-microtubule-associated protein-2
(MAP2; a neuronal marker) antibodies (Chemicon,
Temecula, CA); anti-CCL2 antibodies (R&D Systems);
anti-glial fibrillary protein (GFAP; an astrocyte marker)
antibody (Sternberger Monoclonals, Lutherville, MD);
anti-CD68 (a microglial cell marker) antibody (BD
Pharmingen, San Diego, CA); β-funaltrexamine (β-FNA)
(Tocris, Ellisville, MO); trans-3,4-dichloro-N-methyl-N
[2-(1-pyrolidinyl)cyclohexyl] benzeneacetamide meth-
anesulfonate (U50, 488; a gift from Pharmacia Corp.);
anti-phosphorylated-p38 MAPK antibody (Cell Signaling,
Danvers, MA); and acrylamide/bis solution (Bio-Rad,
Hercules, CA).
Cell cultures
Human fetal brain tissue was obtained from women
undergoing elective abortions, in accordance with
informed-consent guidelines and a protocol approved by
the Human Subjects Research Committee at our institu-
tion.
Highly enriched neuronal cultures were prepared as
described elsewhere [23]. In brief, 15–16-week-old corti-
cal brain tissues were dissociated and resuspended in neu-
ral basal medium containing B-27 serum-free supplement
(contains antioxidants) plus penicillin (100 U/mL) and
streptomycin (100 μg/mL). Dispersed cells were plated
onto collagen-coated plates (5 × 105, 106, or 3 × 106 cells/
well in 24-, 12-, or 6-well plates, respectively) or chamber
slides (4 × 105 cells/well in 4-well chambers). On day 12,
these brain-cell cultures contained ~70–80% neurons
(stained by anti-NeuN or anti-MAP2 antibodies), 15–
25% astrocytes (stained by anti-GFAP antibody), and 3–
7% microglial cells (stained by anti-CD68 antibody). For
highly purified neuronal cultures, on day 5, cell cultures
were treated with uridine (33.6 μg/mL) and fluorodeoxy-
uridine (13.6 μg/mL), followed by replacement with neu-
ral basal medium with B-27 serum-free supplement
(contains antioxidants) on day 6 and every 4 days thereaf-
ter. Highly purified neuronal cultures are >95% neurons,
2–3% astrocytes, and 1–2% microglial cells.
Primary human microglia and astrocyte cultures were pre-
pared as previously described [24]. Briefly, brain tissues
from 16-to-20-week-old aborted fetuses were dissociated
by trypsinization (0.25%) for 30-min and plated into 75-
cm2 Falcon tissue culture flasks in Dulbecco's modified
Eagle's medium (DMEM) containing 10% FBS, penicillin
(100 U/mL), and streptomycin (100 μg/mL). Cells were
incubated for 10–14 days with weekly medium changes.
Microglia floating in the medium were collected, centri-
fuged, and reseeded onto 6-well (2.5 × 106 cells/well), 12-
well (1 × 106 cells/well), or 24-well (0.5 × 106 cells/well)
tissue culture plates with fresh medium. The cultures were
washed 1 h after seeding to remove non-adherent cells.
Microglia cultures were comprised of cells that were >99%
positive for CD68 (a human macrophage marker) andJournal of Neuroinflammation 2006, 3:32 http://www.jneuroinflammation.com/content/3/1/32
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<1% positive for GFAP (an astrocyte marker). To isolate
astrocytes, on day 21, flasks were shaken, washed and
trypsinized with 0.25% trypsin in HBSS for 30 min at 37°.
After adding FBS (final concentration 10%), centrifuga-
tion, and washing, cells were seeded into new flasks with
DMEM followed by medium change after 24 h. The sub-
culture procedure was repeated four times at a weekly
interval. Astrocyte cultures were comprised of cells that
were >99% GFAP-positive.
Cell viability
To assess the effect of morphine at 10-4 M (used in the
immunocytochemical staining experiments) on cell via-
bility two assays were used: Cell Death Detection ELISAP-
LUS (Roche Diagnostics, Indianapolis, IN) and MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide mitochondrial dehydrogenase) (Sigma) assays. The
Cell Death Detection ELISAPLUS  assay was performed
according to the manufacture's instructions. MTT was
added to neuronal cultures at a final concentration of 1
mg/ml, and after 4 h of incubation, the assay was stopped
by adding lysis buffer (20% SDS [w/v] in 50% N, N-dime-
thyl formamide, pH 4.7) followed by overnight incuba-
tion. The absorbance (O.D.) measured at 600 nm reflects
mitochondrial integrity.
RNase protection assay (RPA)
To assess chemokine mRNA expression, total RNA iso-
lated with RNeasy® mini kit (Qiagen, Valencia, CA) from
highly enriched neuronal cultures was used in the multi-
probe RPA according to the manufacturer's protocol (BD
Biosciences PharMingen, San Diego, CA).
ELISA
To measure CCL2 in highly enriched neuronal culture
supernatants, ELISA plates (96-well) were coated with cor-
responding mouse anti-human antibodies (1–2 μg/ml)
overnight at 4°C. The plates were blocked with 1% bovine
serum albumin in PBS for 1 h at 37°C. After washing with
PBS containing Tween 20, culture supernatants and a
series of dilutions of CCL2 as standards were added to
wells for 2 h at 37°C. Following washing, detection anti-
body (goat anti-human CCL2 1–2 μg/ml) was added for
90 min at 37°C followed by donkey anti-goat IgG horse-
radish-peroxidase conjugate (1:10,000) for 45 min. A
chromogen substrate K-blue (Neogen, Lexington, KY) was
then added at room temperature for color development,
which was stopped with 1 M H2SO4. The plate was read at
450 nm to generate standard concentration curves for
CCL2 concentration extrapolation.
Immunocytochemical staining
Highly purified neuronal cultures on 4-chamber slides
were fixed with 4% paraformaldehyde followed by block-
ing with 10% goat serum for 20 min at room temperature.
After washing with PBS, culture slides were incubated with
rabbit anti-MAP2 (1:1000) and mouse anti-CCL2 (10 μg/
ml) antibodies overnight at 4°C. After washing with PBS,
culture slides were incubated with Fluorescein (FITC)-
conjugated goat anti-rabbit IgG (5 μg/ml for MAP2 stain-
ing) and Rhodamine Red X-conjugated goat anti-mouse
IgG (5 μg/ml for CCL2 staining) (Jackson ImmunoRe-
search, West Grove, PA) for 60 min at room temperature.
After washing with PBS, mounting medium (Vector Labo-
ratories, Burlingame, CA) and cover slip were applied for
viewing under fluorescence microscopy.
Statistical analysis
Data are expressed as mean ± SEM or mean ± SD. For com-
parison of means the paired Student t-test was used. For
the data using the MOR antagonist β-FNA, we performed
an ANOVA analysis. Since we expected that β-FNA will
inhibit the effect of morphine, but not controls, we used a
saturated two-factor ANOVA model in order to estimate
the possible interaction. To estimate the mean inhibitory
effect of β-FNA and assess its statistical significance, we
compared the mean difference in morphine-exposed and
control neuronal CCL2 production in the presence and
absence of β-FNA. We used Levene's test to assess the
ANOVA equal variance assumption and R2 to measure
model fit.
Results
Morphine stimulates CCL2 production by human neurons
To determine whether morphine stimulates expression of
CCL2, highly enriched neuronal cell cultures were treated
with morphine (10-8 M or 10-6 M) for 24 h or 48 h fol-
lowed by total RNA isolation for RPA. As shown in figure
1, of the chemokines studied, only CCL2 mRNA was
expressed constitutively and this was the only chemokine
mRNA that was significantly upregulated by morphine
exposure. Using an ELISA to measure CCL2 protein, the
stimulation of CCL2 production by morphine was found
to be both concentration-dependent, with maximal effect
at 10-6 M morphine (Fig. 2) and time-dependent, with the
most robust effect observed at 8 and 24 h (Fig. 3A). To fur-
ther confirm that neurons were producing CCL2 in
response to morphine, immunocytochemical staining
was performed on highly purified (>95%) neuronal cul-
tures, which colocalized CCL2 to cells of a neuronal phe-
notype and further demonstrated that morphine
stimulates neuronal CCL2 production (Fig. 4). The viabil-
ity of the neurons exposed to morphine 10-4 M was con-
firmed by MTT and apoptotic assays (data not shown).
Morphine does not enhance CCL2 production in human 
astrocytes and microglial cells
To further assess if morphine's stimulatory effect on CCL2
production is specific to neurons or more generally affects
CCL2 production by glial cells (microglia and astrocytes),Journal of Neuroinflammation 2006, 3:32 http://www.jneuroinflammation.com/content/3/1/32
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we performed experiments to test morphine's effect on
CCL2 production in primary cell cultures of human
microglial cells and astrocytes. As shown in figure 3B and
3C, while both microglia and astrocytes constitutively
expressed CCL2, morphine exclusively enhanced the
expression of CCL2 in neurons, but not in microglia and
astrocytes.
Morphine stimulation of CCL2 in human neurons involves 
MORs
Having demonstrated that morphine specifically influ-
ences neuronal CCL2 production, we set out to identify if
this process is mediated by the MOR. Using the MOR
selective antagonist, β-FNA, we demonstrated significant
but incomplete blockade of morphine's effect on neuro-
nal CCL2 production (Fig. 5). As morphine also acts at
kappa opioid receptor (KOR)s and delta opioid receptor
(DOR)s, the partial blockade by β-FNA suggests that mor-
phine-induced stimulation of CCL2 production could be
occurring via one or both of these receptors as well as
MORs. That KOR involvement seems unlikely was sug-
gested by an experiment using the KOR ligand U50, 488
(10-6 to 10-12 M) which was found to have no stimulatory
effect on neuronal CCL2 production.
Discussion
The purpose of this study was to explore the influence of
morphine on CCL2 expression by human neurons. Our
focus was on CCL2 primarily because of accumulating evi-
dence of the important role of this chemokine in neuroin-
flammation and the potential involvement of CCL2 as a
communication signal in the cross-talk between the brain
and the immune system. In the course of testing the
hypothesis that morphine would stimulate CCL2 produc-
tion by neurons, three observations were made: 1) CCL2,
which was the only chemokine examined that was consti-
tutively expressed by neurons under our experimental
conditions, was significantly upregulated in neurons by
Concentration-responses of morphine on human neuronal  CCL2 production Figure 2
Concentration-responses of morphine on human 
neuronal CCL2 production. Cell culture supernatants 
were collected from highly enriched neuronal cell cultures 
treated with the indicated concentrations of morphine for 24 
h. Data are mean ± SEM of triplicates of three separate 
experiments using neurons derived from different brain spec-
imens. *P < 0.05, **P < 0.01 versus control.
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Morphine effect on human neuronal chemokine production Figure 1
Morphine effect on human neuronal chemokine pro-
duction. Total RNA (5 μg) isolated from control (C) and 
morphine (10-8, 10-6 M at 24 and 48 h) exposed highly 
enriched neurons were used in RPA with a chemokine tem-
plate. Ltn, lymphotactin; GAPDH glyceraldehydes 3-phos-
phate dehydrogenase.
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exposure to morphine; 2) morphine's enhancement of
CCL2 was specific for neurons, as witnessed by a lack of
response of astrocytes and microglia to morphine under
our experimental conditions; and 3) morphine's potenti-
ation of neuronal CCL2 production involves the MOR.
Morphine has previously been shown to stimulate CCL2
expression in other cell types [5], and other investigators
have shown that neurons constitutively express CCL2 [9-
13]. However, this study demonstrated for the first time
that morphine can stimulate production of CCL2 by
human neurons. Generally, astrocytes and microglia have
been regarded as the main brain cell sources of this impor-
tant chemokine [7], and indeed we demonstrated that
both glial cell populations do express CCL2 constitutively.
Other investigators have shown that the combination of
HIV-1 Tat protein and morphine increased the release of
CCL2 from astrocytes [25] and subsequently promoted
the chemotaxis of microglia [20]. However, they found as
did we, that exposure of astrocytes to morphine alone had
no significant effect on CCL2 production [25]. Further-
more, treatment of human astrocytes with morphine has
been shown by others to downregulate CCL2 mRNA and
protein expression [6].
While the MOR selective antagonist β-FNA significantly
abrogated morphine's effect on neuronal CCL2 produc-
tion, the blockade was only partial. In addition to activat-
ing MORs, morphine has the ability to stimulate KORs
and DORs. Our observation that the KOR selective agonist
U50, 488 did not enhance neuronal CCL2 production,
suggested that morphine's effect is not acting through
KORs. However, this finding doe not preclude the
involvement of DORs or of a non-opioid receptor mecha-
nism in morphine-induced stimulation of CCL2 produc-
tion. Also, there is the possibility that morphine's
stimulatory effect is countered by inhibitory effects of
KORs or DORs activation, as such "yin and yang" effects
have been commonly seen in previous studies of MOR
and KOR agonists in glial cell cultures. Further investiga-
tions will be required to tease out whether any of these
possibilities are operative.
The biological significance of the findings in this study is
unknown, and the results must be interpreted with cau-
tion given the artifactual nature of our in vitro culture sys-
tems. However, one potential implication of the
specificity for neurons of morphine's stimulatory effect on
CCL2 production is that opiates may increase recruitment
of inflammatory cells within the CNS via their effect on
neurons. Such opiate-mediated expression of CCL2 may
hypothetically be beneficial, as demonstrated by the
observation that CCL2 protects human neurons and
astrocytes from NMDA or HIV-tat-induced apoptosis [21],
or deleterious, as CCL2 plays a key role in recruiting HIV-
infected leukocytes into the CNS [15], and recruitment of
inflammatory cells in itself may expose neurons to toxic
mediators [26]. Finally, while the focus on CCL2 in this
study was based on growing evidence of that CCL2 plays
a pivotal role in neuroinflammation, other chemokines
that are produced by neurons, such as the CX3C chemok-
ine fractalkine [27], may also be important signals
whereby neurons recruit inflammatory cells within the
CNS.
Conclusion
Taken together, the findings in this study support the
hypothesis that morphine stimulates CCL2 expression by
human neurons and add another mechanism to a grow-
Effect of morphine on CCL2 production by human neurons,  microglial cells, and astrocytes Figure 3
Effect of morphine on CCL2 production by human 
neurons, microglial cells, and astrocytes. Cell culture 
supernatants were collected from A) highly enriched neuro-
nal cell, B) microglial cell, and C) astrocyte cultures treated 
with medium (control) or morphine (10-6 M) for the given 
time points and assayed for CCL2 by ELISA. Data are mean ± 
SD of triplicates and are representative of three separate 
experiments using cells derived from different brain speci-
mens. **P < 0.01 versus control.
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ing repertoire whereby opiates could alter the neuroin-
flammatory process.
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